Rogers S, Bovee B W, Segal S
Division of Biomedical Development and Molecular Diseases, Children's Hospital of Philadelphia, Pa.
Enzyme. 1989;42(1):53-60. doi: 10.1159/000469007.
Uridine sugar nucleotides are important intermediates in galactose metabolism and may play a role in the long-term galactose toxicity in human galactose-1-phosphate uridyltransferase deficiency galactosemia. Since administration of uridine, a precursor of uridine nucleotides, has been considered as a therapeutic measure, we have investigated the effects of this compound on the activity of rat hepatic transferase. Uridine has been found to be an inhibitor of the enzyme in in vitro studies and to cause an increase in galactose-1-phosphate in liver perfused with galactose which is consistent with physiologic inhibition of the enzyme. Uridine is a partial linear competitive inhibitor of UDPglucose and an uncompetitive inhibitor of galactose-1-phosphate. These findings suggest caution should be applied in giving the compound to subjects with genetically limited transferase activity because of the possibility of inhibiting the small amount of residual enzyme.
尿苷糖核苷酸是半乳糖代谢中的重要中间体,可能在人类1-磷酸半乳糖尿苷转移酶缺乏性半乳糖血症的长期半乳糖毒性中起作用。由于尿苷(尿苷核苷酸的前体)的给药已被视为一种治疗措施,我们研究了该化合物对大鼠肝转移酶活性的影响。在体外研究中发现尿苷是该酶的抑制剂,并且在用半乳糖灌注的肝脏中会导致1-磷酸半乳糖增加,这与该酶的生理抑制作用一致。尿苷是UDP葡萄糖的部分线性竞争性抑制剂和1-磷酸半乳糖的非竞争性抑制剂。这些发现表明,由于有可能抑制少量残留酶,因此在给具有遗传上有限转移酶活性的受试者使用该化合物时应谨慎。